Skip to main content

Table 1 Human and animal studies involving carnitine supplementation to improve female fertility/reproductive status

From: Role of L-carnitine in female infertility

Study aim

Carnitine(s) supplementation (dose and duration)

Study design/Subjects

Outcomes relevant to reproduction


Human Studies

Single center, prospective study to evaluate whether ALC modulates opiatergic pathway in a group of patients with stress-induced amenorrhea

1 g/day ALC orally for 16 weeks

24 patients (aged 21–32 years) with FHA for the last 6 months were subdivided into 2 groups:

Group A (hypogonadotropic patients, plasma LH levels ≤3 mIU/ml, n = 16)

Group B (normogonadotropic patients, plasma LH levels > 3 mIU/ml, n = 8)

• ALC administration significantly modulates GnRH and LH secretion in hypothalamic amenorrhea in hypogonadotropic patients

• ALC probably affects neuroendocrine control of gonadotropin secretion by modulating opiatergic control of GnRH-LH secretion

• Data support the use of ALC as a therapeutic drug for stress-induced reproductive disorders with low LH levels or hypogonadotropic condition


Single center, double blinded, randomized controlled clinical trial to evaluate the effectiveness of LC on improving the ovulation and pregnancy rates as well as adverse metabolic indices in clomiphene-resistant PCOS women

3 g/day LC orally from day three until day seven of the cycle

170 clomiphene resistant PCOS women (aged less than 35 years) were randomly allocated into 2 groups:

Group A (n = 85) received 250 mg clomiphene citrate plus LC

Group B (n = 85) received 250 mg clomiphene citrate with placebo

• The combination of LC and CC significantly improved both the ovulation and the pregnancy rates in clomiphene-resistant PCOS women

• The number of stimulated follicles reaching ≥17 mm diameter was significantly higher in Group A as compared to Group B

• Endometrium at the time of hCG administration was significantly thicker in Group A

• Serum E2, on the day of hCG administration, was significantly higher in the LC group

• Pregnancy occurred in 42/85 cycles in Group A (54.5%) and 5/85 cycles in Group B (5.8%) and the difference was statistically significant.

• The miscarriage rate was lower in Group A (2/85; 2.3%) than in Group B (4/85; 4.7%) (p = 0.67)


Before-after clinical trial to examine the effect of adding LC to PCOS patients who were resistant to clomiphene citrate and gonadotropin

2 g LC orally every 12 h, given from the third day of treatment with clomiphene citrate and gonadotropin until the hCG injection

50 PCOS patients (aged 20–35 years) either received LC or did not receive LC

• LC-treated women experienced the growth of dominant follicles (64%, 32/50 therapeutic cycles) and displayed a positive pregnancy test (20%, 10/50 therapeutic cycles)

• LC-supplemented women had increased left ovarian follicle size compared to those without LC, however right ovarian follicle size was not significantly different between both groups

• LC supplementation increased the mean endometrial thickness compared to those without LC.


Prospective, randomized, double-blind, placebo-controlled trial to determine the effects of oral LC supplementation on weight loss, and glycemic and lipid profiles in women with PCOS

250 mg LC orally for 12 weeks

60 overweight PCOS (aged 18–40 years) were randomized to receive either LC (n = 30) or placebo (n = 30)

• LC supplementation reduced body weight, body mass index, waist circumference and hip circumference and improved glycemic control in PCOS patients compared with placebo.

• LC supplementation did not affect lipid profiles or free testosterone levels compared with placebo


Oral LC supplementation on mental health and biomarkers of OS in women with PCOS

250 mg LC for 12 weeks

60 patients: randomized, double-blind, placebo-controlled study

• LC supplementation improved general and mental health parameters

• LC supplementation improved TAC, MDA/TAC ratio and decreased lipid peroxidation


Animal Studies

LC supplementation on endometriosis in BALB/c mice

25 mg/ml/d LC for 7 days

Young female BALB/c mice of 4–8 weeks of age

• Increased concentration of LC in serum

• Decreased levels of IFN-γ, TNF-α, IL-6, IL-2


LC on reproductive hormones and organs of pregnant mice

0.5 and 1.0 mg/kg LC from day-1 until parturition

Female Swiss albino mice of 12–14 weeks of age

• Significantly increased FSH, LH and estradiol levels

• Increased litter size, weight of reproductive organs and thickness of endometrium


ALC on HPG axis of female Sprague-Dawley rats

50 mg/kg/d ALC for 2 consecutive estrous cycles

Female Sprague-Dawley rats of 3 months of age

Improved hormonal secretions through HPG axis: increased GnRH, LH, estradiol and progesterone levels


LC on OS parameters in oophorectomized rats

100 mg/kg/d LC during post-castration day-21 to -35 (14 consecutive days)

Female adult Wistar rats

Decreased MDA, and NO levels, and improved TAC and OS index


Reproductive performance of sows on LC-supplementation

125 mg/d LC (pregnancy), 250 mg/d LC (lactation)

300 sows (Leicoma)

Improved litter size and piglets' body weight gain, decreased number of stillborn piglets


LC in gestating sow diet on fetal development

50 ppm in diet for 3 reproductive cycles, until day-110 of gestation

232 gestating sows

Increased leanness and muscle density in offspring


Dietary LC on laying hen performance and egg quality

500 mg/kg LC diet for 84 days

180 Isabrown laying hens of 27-weeks of age

Improved egg quality parameters including albumin content


LC on reproductive traits of white leghorns

125 ppm LC until 37-week of age

720 White leghorns

Improved total lipid and LC content in yolk


LC in cows during transition and high lactation period

2 g/d LC for 5 weeks

262 dairy cows (German Holstein)

Improved metabolic status during lactation period, increased milk protein content


  1. ALC, Acetyl-L-carnitine, FHA, Functional hypothalamic amenorrhea, HPG Hypothalamo-pituitary-gonadal axis, LC L-Carnitine, MDA Malondialdehyde, NO Nitric oxide, OS Oxidative stress, PCOS Polycystic ovary syndrome, SCC Somatic cell count, TAC Total antioxidant capacity